Qiagen (NYSE:QGEN) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Qiagen (NYSE:QGEN) issued its quarterly earnings results on Wednesday. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.02, Zacks reports. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same quarter in the prior year, the firm earned $0.60 earnings per share. The company’s quarterly revenue was up .2% compared to the same quarter last year. Qiagen updated its FY 2026 guidance to 2.430- EPS.

Qiagen Price Performance

Shares of NYSE QGEN traded down $0.40 during midday trading on Wednesday, hitting $41.93. The company had a trading volume of 2,037,433 shares, compared to its average volume of 2,895,016. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49. Qiagen has a twelve month low of $32.53 and a twelve month high of $57.81. The business has a 50-day simple moving average of $39.21 and a two-hundred day simple moving average of $41.73. The firm has a market capitalization of $8.64 billion, a price-to-earnings ratio of 21.90, a price-to-earnings-growth ratio of 4.22 and a beta of 0.63.

Qiagen Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th were paid a $0.35 dividend. This represents a dividend yield of 90.0%. This is a positive change from Qiagen’s previous annual dividend of $0.26. The ex-dividend date was Tuesday, July 7th. Qiagen’s dividend payout ratio (DPR) is 18.32%.

Wall Street Analysts Forecast Growth

QGEN has been the subject of a number of analyst reports. Barclays set a $38.00 price objective on shares of Qiagen and gave the stock an “equal weight” rating in a research report on Wednesday, April 29th. Robert W. Baird set a $43.00 target price on shares of Qiagen and gave the company an “outperform” rating in a report on Wednesday, April 29th. Citigroup reiterated a “hold” rating on shares of Qiagen in a research note on Monday, May 18th. Zacks Research raised shares of Qiagen from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 29th. Finally, Berenberg Bank set a $45.50 price objective on Qiagen and gave the company a “hold” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Qiagen presently has a consensus rating of “Hold” and a consensus price target of $43.34.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. First Trust Advisors LP increased its stake in Qiagen by 218.7% in the 4th quarter. First Trust Advisors LP now owns 270,044 shares of the company’s stock valued at $12,144,000 after purchasing an additional 185,298 shares in the last quarter. Public Employees Retirement System of Ohio grew its holdings in Qiagen by 13.5% in the fourth quarter. Public Employees Retirement System of Ohio now owns 248,064 shares of the company’s stock valued at $11,276,000 after purchasing an additional 29,473 shares during the last quarter. PDT Partners LLC increased its position in shares of Qiagen by 142.4% in the second quarter. PDT Partners LLC now owns 110,563 shares of the company’s stock valued at $5,314,000 after buying an additional 64,956 shares in the last quarter. Schonfeld Strategic Advisors LLC raised its stake in shares of Qiagen by 461.7% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 65,147 shares of the company’s stock worth $2,930,000 after buying an additional 53,549 shares during the last quarter. Finally, Verition Fund Management LLC acquired a new position in shares of Qiagen during the 4th quarter worth $2,575,000. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.